Literature DB >> 25806246

Resistance to anti-angiogenic agents: a brief review of mechanisms and consequences.

Martin J Edelman1, Li Mao2.   

Abstract

Year:  2013        PMID： 25806246      PMCID： PMC4367613          DOI： 10.3978/j.issn.2218-6751.2013.01.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 3.  State of the science: an update on renal cell carcinoma.

Authors:  Eric Jonasch; P Andrew Futreal; Ian J Davis; Sean T Bailey; William Y Kim; James Brugarolas; Amato J Giaccia; Ghada Kurban; Armin Pause; Judith Frydman; Amado J Zurita; Brian I Rini; Pam Sharma; Michael B Atkins; Cheryl L Walker; W Kimryn Rathmell
Journal:  Mol Cancer Res       Date:  2012-05-25       Impact factor: 5.852

4.  Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis.

Authors:  F Pezzella; U Pastorino; E Tagliabue; S Andreola; G Sozzi; G Gasparini; S Menard; K C Gatter; A L Harris; S Fox; M Buyse; S Pilotti; M Pierotti; F Rilke
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

Review 5.  Cancer as an evolutionary and ecological process.

Authors:  Lauren M F Merlo; John W Pepper; Brian J Reid; Carlo C Maley
Journal:  Nat Rev Cancer       Date:  2006-11-16       Impact factor: 60.716

6.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors.

Authors:  Oriol Casanovas; Daniel J Hicklin; Gabriele Bergers; Douglas Hanahan
Journal:  Cancer Cell       Date:  2005-10       Impact factor: 31.743

Review 7.  Clonal evolution in cancer.

Authors:  Mel Greaves; Carlo C Maley
Journal:  Nature       Date:  2012-01-18       Impact factor: 49.962

8.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Authors:  John M L Ebos; Christina R Lee; James G Christensen; Anthony J Mutsaers; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-17       Impact factor: 11.205

9.  Pericytes limit tumor cell metastasis.

Authors:  Xiaojie Xian; Joakim Håkansson; Anders Ståhlberg; Per Lindblom; Christer Betsholtz; Holger Gerhardt; Henrik Semb
Journal:  J Clin Invest       Date:  2006-02-09       Impact factor: 14.808

Review 10.  Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  André Bacellar Costa Lima; Ligia T Macedo; André Deeke Sasse
Journal:  PLoS One       Date:  2011-08-02       Impact factor: 3.240
View more
  2 in total

1.  A Quininib Analogue and Cysteinyl Leukotriene Receptor Antagonist Inhibits Vascular Endothelial Growth Factor (VEGF)-independent Angiogenesis and Exerts an Additive Antiangiogenic Response with Bevacizumab.

Authors:  Clare T Butler; Alison L Reynolds; Miriam Tosetto; Eugene T Dillon; Patrick J Guiry; Gerard Cagney; Jacintha O'Sullivan; Breandán N Kennedy
Journal:  J Biol Chem       Date:  2016-12-29       Impact factor: 5.157

2.  Robustaflavone induces G0/G1 cell cycle arrest and apoptosis in human umbilical vein endothelial cells and exhibits anti-angiogenic effects in vivo.

Authors:  Woo Kyung Sim; Jong-Hwa Park; Ki-Young Kim; In Sik Chung
Journal:  Sci Rep       Date:  2020-07-06       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.